Two Sigma Investments
CYTK icon

Two Sigma Investments’s Cytokinetics CYTK Stock Holding History

Two Sigma Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,000
Closed -$1.25M – 3075
2023
Q4 		$1.25M Buy
+15,000
New +$543K ﹤0.01% 1943

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments's CYTK Position: Q1 2026 in Review

Two Sigma Investments increased its Cytokinetics (CYTK) stake by 4% in Q1 2026, buying an estimated $699K and bringing the position to 285,008 shares worth $18.8M. The position accounts for 0.02% of the portfolio, ranked #987.

Two Sigma Investments first reported a position in CYTK in Q3 2013 and has held it in 42 quarters since. The position peaked at $26.8M in Q4 2021. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Two Sigma Investments held 285,008 shares of Cytokinetics worth $18.8M as of Q1 2026.
  • Two Sigma Investments bought 10,991 Cytokinetics shares in Q1 2026, an estimated $699K.
  • Cytokinetics made up 0.02% of Two Sigma Investments's portfolio in Q1 2026, its #987 holding.
  • Two Sigma Investments first reported a position in Cytokinetics in Q3 2013 and has held it in 42 quarters since.
  • Two Sigma Investments's Cytokinetics position peaked at $26.8M in Q4 2021.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.